Tesamorelin Drug Information
The Food and Drug Administration has licensed tesamorelin acetate (EgriftaTM) for the treatment of HIV-associated lipodystrophy. This condition is brought on by the medications used to treat HIV (human immunodeficiency virus) and causes an excessive amount of fat to be deposited around the abdomen (stomach). This medicine is injected subcutaneously in the stomach area once a day.
Prior to beginning treatment with tesamorelin, inform your healthcare provider about any other medical conditions you have or have a history of. People with a history of cancer or pituitary problems, for example, have a higher risk of problems with this medication and may not be able to take it.
(Click Tesamorelin for more information on this drug, including possible side effects, other important safety precautions, and more.)